Efficacy of Scalp Cooling in Preventing Chemotherapy-Induced Alopecia in Breast Cancer Patients Receiving Adjuvant Docetaxel and Cyclophosphamide Chemotherapy

被引:37
|
作者
Cigler, Tessa [1 ]
Isseroff, Devora [1 ]
Fiederlein, Barbara [1 ]
Schneider, Sarah [1 ]
Chuang, Ellen [1 ]
Vandat, Linda [1 ]
Moore, Anne [1 ]
机构
[1] Weill Cornell Med Coll, Div Hematol & Med Oncol, New York, NY USA
关键词
Alopecia; Breast cancer; Chemotherapy; Cold cap; Cryotherapy; INDUCED HAIR LOSS; SYSTEM;
D O I
10.1016/j.clbc.2015.01.003
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Scalp cryotherapy may prevent chemotherapy associated alopecia (CIA). Degree of hair loss in 20 women electing to use scalp cooling during TC chemotherapy for breast cancer was assessed. After completion of chemotherapy only 2 (10%) reported the need to wear a wig or head covering. Scalp cooling appears to be effective in preventing CIA with a common chemotherapy regimen. Background: Chemotherapy-induced alopecia (CIA) is a distressing adverse effect of many chemotherapy agents. The TC (docetaxel [Taxotere] and cyclophosphamide) chemotherapy regimen is typically associated with complete alopecia. Scalp cooling with cold caps has been reported to minimize or prevent CIA. We conducted a prospective study to assess efficacy of scalp cooling in preventing CIA among women receiving adjuvant TC chemotherapy for breast cancer. Methods: Women at the Weill Cornell Breast Center who independently elected to use scalp cooling with cold caps during adjuvant TC chemotherapy were asked to participate. Degree of hair loss was assessed by a single practitioner using Dean's alopecia'scale (grade 1/excellent [< 25% hair loss], grade 2/good [25%-50% hair loss], grade 3/moderate [50%-75% hair loss], grade 4/poor [> 75% hair loss]), by digital photographs, and by patient self-report of hair thinning or the need to wear a wig/head covering, or both. Assessments were made before each chemotherapy treatment and at follow-up visits between 3 weeks and 3 months after completion of chemotherapy. Results: Of 20 evaluable patients, 10% reported a need to wear a wig/head covering at the follow-up visit. Dean's alopecia score was excellent for 65% of patients, good for 25% of patients, and moderate or poor for 10% of patients. The majority of patients reported hair thinning after every chemotherapy cycle. No patient discontinued therapy because of an intolerance to cold caps. Conclusion: Scalp cooling with cold caps appears to be effective in preventing CIA among the majority of women undergoing treatment with TC chemotherapy.
引用
收藏
页码:332 / 334
页数:3
相关论文
共 50 条
  • [21] Dermatologist awareness of scalp cooling for chemotherapy-induced alopecia
    Yin, Lu
    Klein, Elizabeth J.
    Svigos, Katerina
    Novice, Taylor
    Gutierrez, Daniel
    Oratz, Ruth
    Lacouture, Mario E.
    Powers, Molly
    Senna, Maryanne
    Shapiro, Jerry
    Lo Sicco, Kristen
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 88 (01) : 176 - 179
  • [22] Dermatologist awareness of scalp cooling for chemotherapy-induced alopecia
    Yin, Lu
    Svigos, Katerina
    Klein, Elizabeth J.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (03) : AB3 - AB3
  • [23] Cooling of the Scalp to Prevent Anticancer Chemotherapy-induced Alopecia
    Abramov, M.
    Semenova, I.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S321 - S321
  • [24] Correlation of chemotherapy-induced alopecia and quality of life among breast cancer patients undergoing scalp cooling device during chemotherapy
    Yeo, W.
    Mo, F.
    Li, L.
    Lau, T.
    So, H.
    Lui, D.
    Wong, H.
    Leung, E.
    Chan, D.
    Yeo, H.
    Lai, K.
    Pang, E.
    Li, Y.
    Kwok, C.
    EUROPEAN JOURNAL OF CANCER, 2024, 200 : 44 - 45
  • [25] Decreased rates of chemotherapy-induced alopecia in patients receiving chemotherapy (including anthracyclines) with use of scalp-cooling devices
    Deengar, Angad
    Vandat, Linda
    Dulgher, Maxim
    CANCER RESEARCH, 2020, 80 (04)
  • [26] Scalp cooling as a method of avoiding alopecia in cancer patients receiving chemotherapy
    de Vires, N
    Andersen, OK
    EUROPEAN JOURNAL OF CANCER, 2002, 38 : S134 - S135
  • [27] Comment on: “Preventing chemotherapy-induced alopecia: a prospective clinical trial on the efficacy and safety of a scalp-cooling system in early breast cancer patients treated with anthracyclines”
    Jun Kako
    Kohei Kajiwara
    Masamitsu Kobayashi
    Yasufumi Oosono
    British Journal of Cancer, 2019, 121 : 805 - 805
  • [28] Comment on: "Preventing chemotherapy-induced alopecia: a prospective clinical trial on the efficacy and safety of a scalp-cooling system in early breast cancer patients treated with anthracyclines"
    Kako, Jun
    Kajiwara, Kohei
    Kobayashi, Masamitsu
    Oosono, Yasufumi
    BRITISH JOURNAL OF CANCER, 2019, 121 (09) : 805 - 805
  • [29] Clinical Predictors of Chemotherapy-induced Nausea and Vomiting in Breast Cancer Patients Receiving Adjuvant Doxorubicin and Cyclophosphamide
    Shih, Vivianne
    Wan, Hee Siew
    Chan, Alexandre
    ANNALS OF PHARMACOTHERAPY, 2009, 43 (03) : 444 - 452
  • [30] The effectiveness of scalp cooling in preventing alopecia for patients receiving epirubicin and docetaxel
    Macduff, C
    Mackenzie, T
    Hutcheon, A
    Melville, L
    Archibald, H
    EUROPEAN JOURNAL OF CANCER CARE, 2003, 12 (02) : 154 - 161